Patrizia Cavazzoni, leader of the FDA's Center for Drug Evaluation and Research, is leaving the agency on Jan. 18.

In its final days, the Biden administration's FDA is expected to propose a limit on the amount of nicotine in cigarettes.

The FDA’s influential director of the Center for Drug Evaluation and Research, Patrizia Cavazzoni, M.D., will soon retire ...

The director of the FDA's main drug review office will exit on Jan. 18, according to an email sent to staff. Her departure is ...

Following a string of FDA resignations, Patrizia Cavazzoni has announced that her last day will be 18 January.

Dr. Scott Manthei of the Nevada Ear and Sinus Institute has been advising patients against taking drugs like Sudafed for ...

FDA's Center for Drug Evaluation and Research director, Patrizia Cavazzoni, MD, to step down in mid-January. Other top leaders also leaving FDA.

“Based on our review of available data, and consistent with the advice of the advisory committee, we are taking this next step in the process,” said Patrizia Cavazzoni, M.D., director of the ...

supply will also meet or exceed projected demand," Patrizia Cavazzoni, M.D., director of the FDA’s Center for Drug Evaluation and Research, wrote in a letter published on the agency's website.

The FDA recommended patients obtain drugs with "a prescription from their doctor and fill the prescription at a state-licensed pharmacy." Patrizia Cavazzoni, the director of the FDA’s Center for ...

“It is the FDA’s role to ensure that drugs are safe and effective,” Dr. Patrizia Cavazzoni, the director of the FDA’s Center for Drug Evaluation and Research, said in a statement.